Zyversa Therapeutics Stock Performance
| ZVSA Stock | 0.25 0.02 8.70% |
ZyVersa Therapeutics holds a performance score of 9 on a scale of zero to a hundred. The firm maintains a market beta of -0.48, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning ZyVersa Therapeutics are expected to decrease at a much lower rate. During the bear market, ZyVersa Therapeutics is likely to outperform the market. Use ZyVersa Therapeutics expected short fall, as well as the relationship between the rate of daily change and period momentum indicator , to analyze future returns on ZyVersa Therapeutics.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in ZyVersa Therapeutics are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating basic indicators, ZyVersa Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:10 | Last Split Date 2024-04-26 |
1 | Disposition of tradable shares by Larkspur Health Llc of ZyVersa Therapeutics subject to Rule 16b-3 | 11/21/2025 |
2 | ZyVersa Therapeutics Delays 10-Q Filing - MSN | 11/25/2025 |
3 | Why ZyVersa Therapeutics Inc. stock could rally in 2025 - Earnings Recap Summary Weekly High Potential Stock Alerts - DonanmHaber | 12/19/2025 |
4 | Acquisition by Freitag Gregory Gene of 132 shares of ZyVersa Therapeutics at 152.46 subject to Rule 16b-3 | 12/26/2025 |
5 | ZyVersa Therapeutics announces pricing of 2M private placement - MSN | 01/02/2026 |
6 | Disposition of 3427 shares by A.g.p. Alliance Global Partners Corp. of ZyVersa Therapeutics subject to Rule 16b-3 | 01/12/2026 |
7 | Aug Technicals Is ZyVersa Therapeutics Inc stock influenced by commodity prices - July 2025 Selloffs Safe Entry Point Alerts - baoquankhu1.vn | 01/16/2026 |
8 | Can ZyVersa Therapeutics Inc. stock outperform in 2025 bull market - Quarterly Earnings Summary Smart Money Movement Alerts - mfd.ru | 02/10/2026 |
9 | Risk Off What are ZyVersa Therapeutics Incs growth levers - Quarterly Portfolio Review Weekly Momentum Stock Picks - baoquankhu1.vn | 02/18/2026 |
ZyVersa Therapeutics Relative Risk vs. Return Landscape
If you would invest 15.00 in ZyVersa Therapeutics on November 22, 2025 and sell it today you would earn a total of 10.00 from holding ZyVersa Therapeutics or generate 66.67% return on investment over 90 days. ZyVersa Therapeutics is currently generating 1.4557% in daily expected returns and assumes 12.0186% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than ZyVersa, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ZyVersa Therapeutics Target Price Odds to finish over Current Price
The tendency of ZyVersa Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.25 | 90 days | 0.25 | near 1 |
Based on a normal probability distribution, the odds of ZyVersa Therapeutics to move above the current price in 90 days from now is near 1 (This ZyVersa Therapeutics probability density function shows the probability of ZyVersa Stock to fall within a particular range of prices over 90 days) .
ZyVersa Therapeutics Price Density |
| Price |
Predictive Modules for ZyVersa Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ZyVersa Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ZyVersa Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
ZyVersa Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. ZyVersa Therapeutics is not an exception. The market had few large corrections towards the ZyVersa Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold ZyVersa Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of ZyVersa Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.34 | |
β | Beta against Dow Jones | -0.48 | |
σ | Overall volatility | 0.04 | |
Ir | Information ratio | 0.11 |
ZyVersa Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ZyVersa Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for ZyVersa Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| ZyVersa Therapeutics is way too risky over 90 days horizon | |
| ZyVersa Therapeutics has some characteristics of a very speculative penny stock | |
| ZyVersa Therapeutics appears to be risky and price may revert if volatility continues | |
| ZyVersa Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (9.41 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ZyVersa Therapeutics generates negative cash flow from operations | |
| ZyVersa Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Risk Off What are ZyVersa Therapeutics Incs growth levers - Quarterly Portfolio Review Weekly Momentum Stock Picks - baoquankhu1.vn |
ZyVersa Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of ZyVersa Stock often depends not only on the future outlook of the current and potential ZyVersa Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ZyVersa Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.1 M | |
| Cash And Short Term Investments | 1.5 M |
ZyVersa Therapeutics Fundamentals Growth
ZyVersa Stock prices reflect investors' perceptions of the future prospects and financial health of ZyVersa Therapeutics, and ZyVersa Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ZyVersa Stock performance.
| Return On Equity | -1.13 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | (1.3 M) | ||||
| Shares Outstanding | 8.1 M | ||||
| Price To Book | 0.21 X | ||||
| EBITDA | (9.14 B) | ||||
| Net Income | (9.41 M) | ||||
| Total Debt | 12.08 M | ||||
| Book Value Per Share | (1.45) X | ||||
| Cash Flow From Operations | (7.56 M) | ||||
| Earnings Per Share | (3.32) X | ||||
| Market Capitalization | 2.1 M | ||||
| Total Asset | 20.6 M | ||||
| Retained Earnings | (112.63 M) | ||||
| Working Capital | (9.52 M) | ||||
About ZyVersa Therapeutics Performance
By analyzing ZyVersa Therapeutics' fundamental ratios, stakeholders can gain valuable insights into ZyVersa Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ZyVersa Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ZyVersa Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | -5.5 K | -5.3 K | |
| Return On Capital Employed | -1.1 K | -1.1 K | |
| Return On Assets | (525.52) | (499.25) | |
| Return On Equity | -1.3 K | -1.2 K |
Things to note about ZyVersa Therapeutics performance evaluation
Checking the ongoing alerts about ZyVersa Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ZyVersa Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ZyVersa Therapeutics is way too risky over 90 days horizon | |
| ZyVersa Therapeutics has some characteristics of a very speculative penny stock | |
| ZyVersa Therapeutics appears to be risky and price may revert if volatility continues | |
| ZyVersa Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (9.41 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ZyVersa Therapeutics generates negative cash flow from operations | |
| ZyVersa Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Risk Off What are ZyVersa Therapeutics Incs growth levers - Quarterly Portfolio Review Weekly Momentum Stock Picks - baoquankhu1.vn |
- Analyzing ZyVersa Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ZyVersa Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining ZyVersa Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ZyVersa Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ZyVersa Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ZyVersa Therapeutics' stock. These opinions can provide insight into ZyVersa Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ZyVersa Stock analysis
When running ZyVersa Therapeutics' price analysis, check to measure ZyVersa Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ZyVersa Therapeutics is operating at the current time. Most of ZyVersa Therapeutics' value examination focuses on studying past and present price action to predict the probability of ZyVersa Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ZyVersa Therapeutics' price. Additionally, you may evaluate how the addition of ZyVersa Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |